2'-Deoxy-l-adenosine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2'-Deoxy-l-adenosine
• 英文别名: (2S,3S,5S)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
• 化学式: C₁₀H₁₃N₅O₃
• 分子量: 251.24
• InChiKey: OLXZPDWKRNYJJZ-ACZMJKKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20080188440A1

  公开（公告）日：2008-08-07

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  该发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-去氧-β-L-核糖核苷或其药学上可接受的盐或前药，其中2'-去氧-β-L-核糖核苷的化学式为：其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种可以选择性地取代的嘌呤或嘧啶碱基。2'-去氧-β-L-核糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-去氧-β-L-核糖核苷或与另一种抗乙型肝炎药物联合使用。
• BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
  申请人：Gosselin Gilles

  公开号：US20120264707A1

  公开（公告）日：2012-10-18

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗乙肝病毒生物活性2'-脱氧-β-L-赤霉糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-赤霉糖核苷的化学式为：其中R选自H，直链、支链或环烷基，CO-烷基，CO-芳基，CO-烷氧基烷基，CO-芳氧基烷基，CO-取代芳基，烷基磺酰基，芳基磺酰基，芳基烷基磺酰基，氨基酸残基，单、二或三磷酸盐或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可以选择性地被取代。2'-脱氧-β-L-赤霉糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-赤霉糖核苷或其他抗乙肝药物联合使用。
• US7795238B2
  申请人：——

  公开号：US7795238B2

  公开（公告）日：2010-09-14
• US9290533B2
  申请人：——

  公开号：US9290533B2

  公开（公告）日：2016-03-22